Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Sales and Divestitures: 2011-2016

Historic Gains from Sales and Divestitures for Agios Pharmaceuticals (AGIO) over the last 6 years, with Dec 2016 value amounting to $7,500.

  • Agios Pharmaceuticals' Gains from Sales and Divestitures fell 11.99% to $7,500 in Q4 2016 from the same period last year, while for Dec 2016 it was $7,500, marking a year-over-year decrease of 11.99%. This contributed to the annual value of $7,500 for FY2016, which is 11.99% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $7,500 for FY2016, which was down 11.99% from $8,522 recorded in FY2015.
  • Over the past 5 years, Agios Pharmaceuticals' Gains from Sales and Divestitures peaked at $183,713 during FY2012, and registered a low of $7,500 during FY2016.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $8,522 (2015), whereas its average is $10,265.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Gains from Sales and Divestitures rose by 1.04% in 2012, and later plummeted by 89.20% in 2014.
  • Agios Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $183,713 in 2012, then dropped by 25.56% to $136,758 in 2013, then plummeted by 89.20% to $14,773 in 2014, then plummeted by 42.31% to $8,522 in 2015, then fell by 11.99% to $7,500 in 2016.